Similarly, both CD4+ and CD8+ T cells against mutated NPM1 have been found in AML patients [20], and the majority of these cells are effector memory and central memory T cells, which may contribute to the maintenance of long-lasting remissions [61]. The gene discussed is CD8A; the disease is acute myeloid leukemia.